WERTH, V.; PIKE, M.; MERRILL, J.; MORAND, E.; VAN VOLLENHOVEN, R.; HOBAR, C.; DELEV, N.; SHAH, V.; SHARKEY, B.; WEGMAN, T.; CATLETT, I.; BANERJEE, S.; SINGHAL, S. Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: Results from a phase 2, randomized, double-blind, placebo-controlled study. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s114, 2023. DOI: 10.25251/skin.7.supp.114. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/1964. Acesso em: 4 jul. 2024.